Metastasis: recent discoveries and novel treatment strategies
SA Eccles, DR Welch - The Lancet, 2007 - thelancet.com
Most cancer deaths are due to the development of metastases, hence the most important
improvements in morbidity and mortality will result from prevention (or elimination) of such …
improvements in morbidity and mortality will result from prevention (or elimination) of such …
[HTML][HTML] ErbB receptors: from oncogenes to targeted cancer therapies
Understanding the genetic origin of cancer at the molecular level has facilitated the
development of novel targeted therapies. Aberrant activation of the ErbB family of receptors …
development of novel targeted therapies. Aberrant activation of the ErbB family of receptors …
[HTML][HTML] IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway
TNFα has recently emerged as a regulator linking inflammation to cancer pathogenesis, but
the detailed cellular and molecular mechanisms underlying this link remain to be elucidated …
the detailed cellular and molecular mechanisms underlying this link remain to be elucidated …
The tuberous sclerosis complex
KA Orlova, PB Crino - Annals of the New York Academy of …, 2010 - Wiley Online Library
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that results from
mutations in the TSC1 or TSC2 genes and is associated with hamartoma formation in …
mutations in the TSC1 or TSC2 genes and is associated with hamartoma formation in …
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent …
L Gianni, GH Romieu, M Lichinitser… - Journal of clinical …, 2013 - ascopubs.org
Purpose The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With
Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast …
Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast …
Molecular interactions in cancer cell metastasis
SA Brooks, HJ Lomax-Browne, TM Carter, CE Kinch… - Acta histochemica, 2010 - Elsevier
Metastasis, the process by which cancer cells leave the primary tumour, disseminate and
form secondary tumours at anatomically distant sites, is a serious clinical problem as it is …
form secondary tumours at anatomically distant sites, is a serious clinical problem as it is …
The role of the EGFR signaling in tumor microenvironment
A De Luca, A Carotenuto, A Rachiglio… - Journal of cellular …, 2008 - Wiley Online Library
The epidermal growth factor receptor (EGFR) family comprehends four different tyrosine
kinases (EGFR, ErbB‐2, ErbB‐3, and ErbB‐4) that are activated following binding to …
kinases (EGFR, ErbB‐2, ErbB‐3, and ErbB‐4) that are activated following binding to …
[HTML][HTML] PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer
Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in
HER2-overexpressing breast cancer. Because PTEN opposes the downstream signaling of …
HER2-overexpressing breast cancer. Because PTEN opposes the downstream signaling of …
Trastuzumab combined with ramucirumab and paclitaxel in patients with previously treated human epidermal growth factor receptor 2–positive advanced gastric or …
PURPOSE Trastuzumab-containing chemotherapy is the recommended first-line regimen for
human epidermal growth factor receptor 2 (HER2)–positive advanced gastric or …
human epidermal growth factor receptor 2 (HER2)–positive advanced gastric or …
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain
D Palmieri, JL Bronder, JM Herring, T Yoneda, RJ Weil… - Cancer research, 2007 - AACR
Retrospective studies of breast cancer patients suggest that primary tumor Her-2
overexpression or trastuzumab therapy is associated with a devastating complication: the …
overexpression or trastuzumab therapy is associated with a devastating complication: the …